Jagsonpal Pharmaceuticals Allots 94,000 Equity Shares Under Employee Stock Option Plan
Jagsonpal Pharmaceuticals Limited has announced the allotment of equity shares pursuant to the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022 (JPL ESOP 2022). The action resulted in an increase in the company's paid-up share capital.The Nomination and Remuneration Committee issued and allotted 94,000 Equity Shares of Rs. 2/- each to eligible employees upon the exercise of vested options under the JPL ESOP 2022. These newly issued shares are confirmed to rank pari passu with the company's existing equity shares in all respects.
The allotment updated the company’s share capital structure, increasing its paid-up amount. The previous paid-up share capital was Rs. 13,16,70,940, which comprised 6,58,35,470 equity shares of Rs. 2/- each.
Following the allotment, the company’s total paid-up share capital reached Rs. 13,18,58,940, comprising a total of 6,59,29,470 equity shares.
Key details of the shares issued under this plan are presented below:
| Detail | Value |
|---|---|
| Scheme Title | Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022 |
| Issue Date of Shares | July 15, 2026 |
| Number of Shares Issued | 94,000 |
| Par Value per Share | Rs. 2/- |
The shares granted under the plan are identical in all respects to existing shares and rank pari passu with them.
JAGSNPHARM Stock Price Movement
Jagsonpal Pharmaceuticals Limited shed 0.84% in trading, settling at ₹224.31 today. The equity traded within a range of ₹222.71 and ₹232 during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.